Neurocognitive Assessment Platform 4 Alzheimer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.

The Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data.

The study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cohort Study on Cognitive Decline in Elderly

NCT07093892

Alzheimer's Disease，Mild Cognitive Impairment

NOT_YET_RECRUITING

PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning

NCT05569083

Cognitive Decline Mild Cognitive Impairment Alzheimer Disease

UNKNOWN

Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease

NCT04597827

Semantic Dementia Alzheimer Disease Healthy

COMPLETED

Cognitive Impairment in Ageing People

NCT04360200

MCI Alzheimer Disease VAD - Vascular Dementia +1 more

RECRUITING

Home-based Cognitive Treatment and Cognitive Impairment

NCT04889560

Cognitive Impairment

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MCI MCI Conversion to Dementia AMCI - Amnestic Mild Cognitive Impairment Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aMCI patients

Individuals diagnosed with single- or multi-domain amnestic MCI (aMCI)

No interventions assigned to this group

Healthy Controls

Healthy individuals (with similar sex, age, and education level to the aMCI group)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signature of informed consent
* Age between 55 and 80 years
* Absence of functional impact on daily living activities or minimal impact on instrumental activities

* Normal global cognitive efficiency (Mini Mental State Examination scores of 28 or higher)
* Absence of specific cognitive deficits (memory and other cognitive domains) that are abnormal for age, sex, and education level (1.5 standard deviations below the mean for age- and education-matched controls), as assessed by objective, standardized cognitive tests.

* Cognitive difficulties reported by the individual, their family member, or their primary care physician
* Normal global cognitive efficiency (Mini Mental State Examination score within 0.5 standard deviations of the average for age- and education-matched control subjects).
* Specific cognitive deficits related to memory or multi-domain cognitive impairments (involving memory and other cognitive domains) that are atypical for the individual's age (1.5 standard deviations below the average for age- and education-matched controls), as determined by objective, standardized cognitive tests.

Exclusion Criteria

* Rejection of informed consent
* Important sensory deficits (e.g., hearing loss or hypovisus)
* Current or previous history of psychiatric illness
* Current or previous degenerative pathology of the central nervous system (CNS)
* Presence of systemic diseases in anamnesis
* Presence of cerebrovascular events in anamnesis
* Use of alcohol or psychotropic substances in anamnesis

Minimum Eligible Age

55 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes